Clinical Trial Update: CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CPX-351 in combination with glasdegib for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes or therapy-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Myelodysplasia-related Changes
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)
• Glasdegib (Daurismo) (glasdegib)

Snippet

Sponsor: University of California, Irvine | Conditions: Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-06